# A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

> **NCT01185158** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 46 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** ZD1839 (IRESSA)

## Key facts

- **NCT ID:** NCT01185158
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2004-08
- **Final completion:** 2010-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01185158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01185158, "A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01185158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*